Latest on Pharmaceutical Industry


Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases

Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a partnership to discover and develop novel therapeutics for liver diseases, incl..Read More...

Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks

Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed stemmed from her use of the company’s talc-based products like Johns..Read More...



PHARMATechExpo 2017

KyivExpoPlaza Exhibition Center,
LMT Company


Lab Complex 2017

Kyiv Expo Plaza,
LMT Company

Press Releases

Acerus Announces Licensing of NATESTO® in South East Asian Countries

Acerus Pharmaceuticals Corporation announced the signing of an agreement granting Eu Hwa Pte LTD EU the exclusive right to market NATESTO in Thailand MalaysiaBrunei Singapore Vietnam Philippines Hong KongMacau and one ot.. Read More...

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis ALS at the Massachusetts General Hospital a.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics